Mesoblast closes IPO, raises $21 million
Wednesday, 08 December, 2004
Stem cell company Mesoblast today announced that its Initial Public Offer had closed fully subscribed, raising $21 million.
Of the funds, $10 million will be used to acquire a 33 per cent share in founder Silviu Itescu's US-based company Angioblast, which is developing cardiovascular applications for mesenchymal stem cells. The remainder will be used to develop orthopaedic applications for the stem cells.
Itescu said he was delighted with the evident endorsement of the company's strategy to commercialise adult stem cell technology developed by scientists at the Hanson Institute and the Institute of Medical and Veterinary Science in Adelaide.
The IPO was fully underwritten by Lodge Partners.
Cancer drug enters clinical trials based on a false mechanism
A cancer drug currently being tested in patients appears to have entered clinical trials based on...
Russia insists there is "no plague case" following lab worker death
Russian health authorities say there is no evidence that pneumonic plague played a part in the...
Scientists 'reprogram' tumour-supporting immune cells
The approach, by an Australian team, uses lipid nanoparticles to target a type of immune cell...
